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Background: Hepatitis C virus (HCV) infection is associated with an increased risk of primary 
liver cancer; however, 5- and 10-year risk estimates are needed. The association of HCV with non-
Hodgkin lymphoma (NHL) is uncertain and the association with other cancers is unknown.
Method: We conducted a nationwide, population-based cohort study of 4,349 HCV-infected 
patients in Denmark, computing standardized incidence ratios (SIR) of cancer incidence in HCV 
infected patients compared with cancer incidence of the general population. We calculated 5- 
and 10-year risks of developing cancer, stratifying our analyses based on the presence of HIV 
coinfection and cirrhosis.
Results: We recorded an increased risk of primary liver cancer (SIR: 76.63 [95% CI: 
51.69–109.40]), NHL (SIR: 1.89 [95% CI: 0.39–5.52]), and several smoking- and alcohol-related 
cancers in HCV infected patients without HIV coinfection. HCV-infected patients without HIV 
coinfection had a 6.3% (95% CI: 4.6%–8.7%) risk of developing cancer and 2.0% (95% CI: 
1.1%–3.8%) risk of developing primary liver cancer within 10 years.
Conclusion: We confirmed the association of HCV infection with primary liver cancer and 
NHL. We also observed an association between HCV infection and alcohol- and smoking-related 
cancers.
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The association between hepatitis C virus (HCV) infection and the risk of   hepatocellular 
carcinoma (HCC) was established in case control studies,1–3 soon after the discovery of 
HCV4 in 1989. Recent large scale cohort studies in Australia5 and Sweden6 have yielded 
differing estimates of the risk of HCC in HCV infected patients ranging from a 23-fold 
to a 35-fold increased risk. Only in the Australian study were the risk estimates for 
HIV coinfection adjusted (by excluding data from high HIV prevalence postcodes of 
residence), only in the Swedish study were absolute risk estimates of cancer provided, 
and in none of these was information on cirrhosis at baseline   provided. Therefore, areas 
of uncertainty still exist. Further, the relative risk of developing primary liver cancer 
increases in relation to time of HCV infection, making the risk estimates dependent 
on the particular HCV epidemiology of the particular region.6 Therefore estimates of 
the association between HCV and primary liver cancer need to be examined in several 
study settings.
It is unclear whether HCV infection increases the risk of non-Hodgkin lymphoma 
(NHL); HCV infection has been associated with NHL in some,7,8 but not all, studies.5 
In two meta analyses, the association differed depending on HCV prevalence in the 
study population and study designs.9,10 Examining whether there is an association in 
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new nationwide, population-based settings therefore is of 
great importance.
HCV infection is often associated with a number of 
  lifestyle factors, particularly in drug users who consume 
drugs via injections.11,12 Therefore, HCV-infected patients 
could be at increased risk of getting cancer, not only due to 
the pathogenic effect of the virus,13,14 but also due to a higher 
degree of exposure to alcohol abuse and smoking than those 
in the general population.15–19
We therefore undertook a nationwide, population-based 
cohort study with long term follow up to estimate the r  elative 
risk of development of cancers in HCV infected persons 
p  resenting to the hospital system compared to the general 
population. We expected an increased risk of primary liver 
cancer, of smoking- and alcohol-related cancers, and p ossibly 
of NHL, but not of other cancers in comparison to the general 
population. We estimated absolute risks of primary liver cancer, 
adjusting for HIV c  oinfection and including information on 
cirrhosis. These data are needed to foster our understanding 
of the clinical course of HCV infection.
Method
We used the unique 10 digit civil registration number 
assigned to all individuals in Denmark to link the databases 
discussed below.20
The Danish National Hospital Registry
Since its inception in 1977, the Danish National Hospital 
R  egistry (DNHR) has collected data from all inpatient 
a  dmissions to non-psychiatric hospitals in Denmark.21 Data 
from outpatient and emergency department visits were 
added in 1995. Each admission record includes the dates 
of a  dmission (or start of an outpatient contact), date of 
d  ischarge, and up to 20 diagnoses (one of which is desig-
nated as the primary diagnosis), classified according to the 
Danish version of the international classification of diseases, 
8th r  evision (ICD-8) until Dec 31, 1993, and 10th version 
(ICD-10) thereafter. Diagnoses are coded by the treating 
physician. As HCV was discovered in 1989, it does not have 
a separate code in the ICD-8 (however acute HCV was often 
coded as non-A, non-B acute hepatitis), but in ICD-10 both 
acute and chronic HCV infections have separate codes.
The Danish Cancer Registry
The Danish Cancer Registry has recorded data on all cancers 
diagnosed in Denmark since 1943.22 Cancers are classified 
according to the modified Danish version of the international 
classification of diseases, 7th revision (ICD-7) by hospital 
departments and practising physicians. Comprehensive 
assessment has shown the registry to be 95%–98% complete 
and valid.22
study population
We included all people listed in DNHR with at least one 
diagnosis of acute or chronic HCV infection (ICD-10 B17.1 
and 18.2) between 1994 and 2003 (inclusive). Through links 
to the cancer registry, we excluded patients who had had a 
previous diagnosis of cancer.
statistical analyses
We followed cases for the occurrence of cancer from the 
date of first registration of HCV in DNHR (admission, 
o  utpatient clinic, or emergency department) until the date 
of death, emigration, or HIV coinfection or until Dec 31, 
2003, whichever came first. We censored HCV infected 
patients at time of HIV coinfection, as HIV infection is 
associated with several cancers (including NHL and pri-
mary liver cancer) and because our main objective was to 
describe the risk of cancer in HCV infected patients, and 
not in HIV-HCV coinfected patients.23,24 We calculated the 
expected number of cases of cancer after a diagnosis of 
HCV infection using Danish incidence rates of first cancer 
diagnoses according to sex, age, and year of diagnosis in 
1-year intervals. Multiplication of the number of years of 
follow-up by the incidence rates yielded the number of 
people with cancer that would be expected if patients with 
HCV infection had the same rate of cancer as the general 
population.25 We used the standardised incidence ratio – the 
ratio of observed number of cancers to expected number of 
cancers – to measure the a  ssociation between HCV infec-
tion and cancer, and calculated a 95% CI on the basis of the 
assumption that the observed number of cancers in a specific 
category followed a Poisson d  istribution. Exact 95% CI were 
used throughout the study, unless the observed number of 
cancers was 10 or more, in which case Byar’s correction was 
used.26 For cancer sites with 5 or more recorded cases, SIRs 
were further computed for the first year of observation and 
for the s  econd year of observation and onwards. Cancers 
were divided into the following subgroups as specified in 
Appendix 1: Hematological cancers, liver-related cancers, 
alcohol- and tobacco-related cancers, immune-related can-
cers, and other cancers. We stratified our analyses accord-
ing to whether the patients had been previously diagnosed 
with HIV, since HIV coinfection has a substantial impact 
on morbidity and m  ortality in HCV coinfected patients.27–29 
For those not previously infected with HIV, we stratified our 
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analyses according to whether the first HCV diagnosis was 
acute HCV infection or chronic HCV infection and whether 
or not they had cirrhosis at baseline. We estimated cumula-
tive risks using the life-table method.
Results
We identified a total of 4,349 patients with HCV infection 
in the DNHR. Median age at diagnosis was 39.9 years and 
median follow up was 3.3 years (interquartile range [IQR] 
1.3–5.7). A total of 2,721 (63%) of patients were males. There 
were 4,043 patients (93%) aged between 20 and 60 years 
of age at study entry. A total of 105 incident cancers were 
recorded during 16,267 years of observation. During follow 
up, 19 patients were diagnosed with HIV .
HCV-infected patients without HIV 
coinfection at baseline
Overall cancer
A total of 100 cancers were recorded during 15,980 years of 
observation in the 4,204 HCV-infected patients without HIV 
coinfection at baseline (SIR [standardized incidence ratio]: 
1.78, 95% CI: 1.45–2.17). Of these 4,204 patients, 507 were 
diagnosed with acute HCV infection and the remaining 3,697 
were diagnosed with chronic HCV infection. In these groups, 
14 and 86 cancers were recorded with corresponding SIRs 
of 1.88 (95% CI: 1.03–3.15) and 1.77 (95% CI: 1.42–2.19), 
respectively. All cancers recorded in HCV-infected patients 
without HIV at baseline are illustrated in Table 2. In Table 3 
the most   frequently recorded cancers ($5 recorded cancers) 
are recorded for the HCV infected patients without HIV at 
b  aseline, and in Table 4 the most frequently recorded cancers 
($5 recorded cancers) are illustrated for the   chronically 
HCV-infected patients without HIV at baseline. HCV 
  infection was   associated with cancers in all age groups and 
both sexes were at increased risk of cancer (Table 1). Men 
who were infected with HCV , however, had a more than 2-fold 
increased risk whereas women who were infected with HCV 
had a 1.4-fold increased risk of cancer. The absolute 5- and 
10-year risks of developing all-type cancer in HCV-infected 
patients without HIV was 2.9% (95% CI: 2.3–3.7%) and 6.3% 
(95% CI: 4.6%–8.7%). The SIR of cancer in patients with 
a diagnosis of cirrhosis at time of HCV diagnosis was 1.64 
(95% CI: 1.31–2.03) whereas the SIR of cancer in patients 
without cirrhosis was 3.27 (95% CI: 1.87–5.31).
Liver cancer
Compared to the general population, HCV infection was 
  associated with a 77-fold increase in risk of primary liver 
  cancers. For women, the expected number of cases was 0.10 
and the observed number of cases was 10 (SIR: 101.83, 95% 
CI: 48.75–187.29). For men the expected number of cases 
was 0.29 and the observed number of cases was 20 (SIR: 
68.19, 95% CI: 41.64–105.33). No primary liver cancers 
were recorded in patients under the age of 30; in all other age 
groups there was an increased risk of primary liver cancers 
(not shown). Also non-primary liver cancer was associated 
with HCV infection. The absolute 5- and 10-year risks of 
developing primary liver cancer in HCV-infected patients 
without HIV was 0.8% (95% CI: 0.5%–1.2%) and 2.0% (95% 
CI: 1.1%–3.8%). The SIR of primary liver cancer in patients 
with a diagnosis of cirrhosis at time of HCV diagnosis was 
53.88 (95% CI: 32.43–84.15) whereas the SIR of primary 
liver cancer in patients without cirrhosis was 288.99 (95% 
CI: 144.07–517.12).
Table 1 standardized incidence ratios (sIR) for all cancers after a diagnosis of HCV infection (in patients without HIV) according to 
sex and age at the time of admission







Total 4,204 100 56.12 1.78 (1.45–2.17)
Acute vs chronic HCV infection
  Acute 507 14 7.45 1.88 (1.03–3.15)
  Chronic 3,697 86 48.57 1.77 (1.42–2.19)
Sex
  Women 1577 38 27.24 1.39 (0.99–1.91)
  Men 2627 62 28.88 2.15 (1.65–2.75)
Age (years)†
  0–29 717 3 1.10 2.74 (0.56–7.99)
  30–49 2,766 41 23.04 1.78 (1.28–2.41)
  50–69 610 34 22.23 1.53 (1.06–2.14)
  70+ 111 22 9.74 2.26 (1.41–3.42)
†Age at time of diagnosis of HCV infection.
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Hematological cancers
HCV-infected patients carried a doubled risk of NHL; 
however the 95% CI margins were very wide for this 
estimate.
Alcohol and tobacco-related cancers
Cancers of the pancreas, lungs, kidneys, and oropharyngeal 
region were associated with HCV infection. Lung cancers 
represented most recorded cases, with 9 cases among men 
(SIR: 2.90, 95% CI: 1.33–5.50) and 1 case among women 
(SIR: 0.49, 95% CI: 0.01–2.74).
Immune-related and other cancers
There was no convincing association between HCV infection, 
immune-related cancers, and other cancers.
HCV-infected patients with HIV 
coinfection at baseline
Five cancers were recorded during 288 years of follow up in 
the 145 patients who were HIV coinfected at   baseline (SIR: 
8.9, 95% CI: 2.9–20.6). These were primary liver cancer (n = 1, 
SIR: 319.08, 95% CI: 8.07–1,777.03), other skin   cancers than 
melanoma (n = 1, SIR: 9.04, 95% CI: 0.23–50.36), NHL 
(n = 2, SIR: 99.72, 95% CI: 12.07–359.97), and oropharyngeal 
cancer (n = 1, SIR: 50.35, 95% CI: 1.27–280.46).
Discussion
Our results indicate that HCV infected patients have an 
increased risk of cancer compared to the general population 
with a 10-year risk of about 6%. The increased risk of cancer 
was mainly due to a few cancer types, most prominently 
Table 2 All observed cancers in HCV-infected patients without HIV at baseline and corresponding standardized cancer incidence 
ratios
Observed Expected Standardized incidence 
ratio (95% CI)
All neoplasms 140–205 100 56.12 1.78 (1.45–2.17)
Hematological cancers
  Non-Hodgkin lymphoma (200, 202) 3 1.59 1.89 (0.39–5.52)
  Leukemia (204) 1 1.17 0.85 (0.02–4.74)
Liver cancer
  Liver, primary (155.0) 30 0.39 76.63 (51.69–109.40)
  Liver, not specified as primary (156) 3 0.38 7.84 (1.62–22.90)
Alcohol- and tobacco-related cancers
  Oropharyngeal (140–148) 4 1.73 2.32 (0.63–5.93)
  Esophagus (150) 1 0.60 1.65 (0.04–9.22)
  Colon, including recto sigmoid (153) 3 2.95 1.02 (0.21–2.97)
  Rectum, excluding anus (154) 3 1.63 1.85 (0.38–5.39)
  Pancreas (157) 4 1.01 3.95 (1.07–10.11)
  Lung (162.0–162.1) 10 5.14 1.95 (0.93–3.58)
  Kidney (180) 4 1.11 3.60 (0.98–9.22)
  Bladder (181) 2 2.18 0.92 (0.11–3.31)
Immune-related cancers
  Cervix uteri (171) 1 1.30 0.77 (0.02–4.29)
  Melanoma of skin (190) 1 2.99 0.33 (0.01–1.86)
  Other skin (191) 9 10.60 0.85 (0.39–1.61)
Other cancers∗
  Gallbladder (155.1) 1 0.19 5.25 (0.13–29.22)
  Peritoneum and unspecified (158–159) 1 0.11 9.34 (0.24–52.01)
  Mediastinum (164) 1 0.05 21.22 (0.54–118.22)
  Breast (170) 2 8.05 0.25 (0.03–0.90)
  Corpus uteri (172) 1 0.83 1.21 (0.03–6.72)
  Ovary (175) 1 1.07 0.94 (0.02–5.21)
  Prostate (177) 2 1.95 1.02 (0.12–3.70)
  Testis (178) 1 1.59 0.63 (0.02–3.51)
  Other and unspecified male genitals (179) 1 0.10 9.71 (0.25–54.06)
  Brain and nervous system (193) 5 2.40 2.08 (0.68–4.86)
  Thyroid (194) 1 0.46 2.16 (0.05–12.01)
  Metastases (198) 2 0.62 3.23 (0.39–11.66)
  Other and unspecified site (199) 2 0.58 3.43 (0.42–12.39)
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primary liver cancer with an estimated 10-year risk of 2%. 
Further, HCV infection was associated with NHL and cancers 
related to smoking and alcohol use (cancers of the pancreas, 
lungs, kidneys, and oropharyngeal region).
Limitations
Our study has some limitations. Due to the subclinical 
nature of HCV , some infections go unrecognized30 resulting 
in underreporting of HCV .31,32 Such underreporting of HCV 
infection could influence the estimated associations we 
recorded, if those who were not reported were at a different 
risk of cancers compared to those who were recorded. While 
underreporting might have some influence on our results, we 
find it unlikely that underreporting is the main explanation 
of our findings. As another consequence of the subclinical 
nature of HCV , we lacked data on dates of infection/serocon-
version.33 This could have exaggerated our SIR estimates, if 
patients were diagnosed with HCV infection on diagnosis 
of the initial symptoms of cancer. This is certainly possible, 
given the finding that SIRs for all cancer types and for liver 
cancer were greater in the first year of diagnosis compared 
to the following years; however, we find it unlikely that this 
phenomenon is the main explanation of our findings, as SIRs 
remained elevated also beyond 1 year of observation. Further, 
our estimates are useful from a clinical point of view, as they 
describe the risk of cancer upon diagnosis. A final concern 
could be that the observed associations could represent 
surveillance/diagnostic bias (ie, differential misclassifica-
tion of outcome).34 However, we could not demonstrate any 
association between HCV infection and immune related 
cancers which speaks against surveillance/diagnostic bias as 
a general phenomenon explaining our results.35 By censoring 
patients at time of HIV coinfection we may have introduced 
informative censoring, causing us to underestimate HCV 
infected patients’ risk of non-Hodgkin lymphoma, for which 
HIV is a strong risk factor.23,24 However, only 19 patients 
were censored because of HIV coinfection, so – considering 
the size and direction of this bias – it could not have had a 
clinically significant impact on our conclusions.
Discussion of our results  
and the literature
We recorded a substantially increased risk of primary liver 
cancer. Thereby we corroborate the findings from other 
population-based studies in Sweden and Australia.5,6 Our 
overall SIR was 2-fold that of the Swedish study and our 
SIR from the second year of observation and onwards was 
approximately 2.5-fold that of the Australian study.5,6 Dif-
ferent risks of cancer in the general population in Australia, 
Sweden, and Denmark, and differences in HCV notification, 
age at inclusion, and time with infection prior to diagnosis 
(and thereby study inclusion) in these two studies and ours are 
possible explanations for these differences. Moreover, none of 
the studies (ours or those taken from the literature) included 
data on active HCV replication, and differences in the propor-
tion that cleared the infection might explain the differences 
in the SIRs recorded. Finally, differences in the proportion of 
patients with alcohol abuse could explain the higher risks of 
liver cancer in our study.36 The recorded 5-year risk of liver 
cancer in our study (,1%) was much smaller than the 5 year 
risk of approximately 5% in the HALT-C Trial.37 This differ-
ence potentially reflects the more advanced stage of HCV 
infection in patients included in the HALT-C Trial compared 
to our study. However, risk estimates from population based 
settings as ours are important, as they apply for the patient 
upon diagnosis. Surprisingly, HCV infected patients without 
cirrhosis were at an exceptionally high risk of primary liver 
cancer. The reason for this is not clear. Probably some of these 
Table 3 standardized cancer incidence ratios (sIR) for HCV-
infected patients without HIV at baseline
First year after 
HCV diagnosis
More than 1 year 
after HCV 
diagnosis
N SIR (95% CI) N SIR (95% CI)
























∗sites with 5 or more recorded cancers.
Table 4 standardized cancer incidence ratios (sIR) for patients 
with chronic HCV infection without HIV
First year after 
HCV diagnosis
More than 1 year 
after HCV 
diagnosis
N SIR (95% CI) N SIR (95% CI)


















∗sites with 5 or more recorded cancers.
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patients were in fact cirrhotic at the time of HCV diagnosis, 
presenting at an advanced stage of liver disease.
We observed an increased risk of NHL in HCV infected 
patient without HIV , which confirms the findings of others.7–10 
This association could be caused by lifestyle factors in 
the HCV-infected population, a causal effect of the HCV 
i  nfection or both.8,38–41 Importantly, we were able to address 
the issue of HIV coinfection. NHL is an AIDS defining 
  illness, and is highly associated with HIV .23 The i  mportance 
of i  ncorporating HIV coinfection in the risk analysis is 
i  llustrated by a 100-fold increased risk in the coinfected 
group and 2-fold increased risk in the HCV monoinfected 
patients compared to the general population.
We observed an increased risk of cancers related to s  moking 
and alcohol (cancers of the pancreas, lungs, kidneys, and 
oropharyngeal region). Most likely, the increased risk of these 
cancers represents a higher prevalence of alcohol abuse and 
smoking in the HCV-infected patients compared to the general 
population.11,12,15–19,42,43 However, our data sources included only 
DNHR diagnosis and no further clinical data. Therefore we 
were unable to address the potential effects of alcohol abuse and 
smoking in our study. Lung cancers were the most frequently 
recorded smoking-related cancer, with men, but apparently 
not women, at increased risk. This could indicate an uneven 
distribution of smoking in the two groups.
Conclusion
In summary, we found an association between HCV infection 
and cancer, mainly by confirming the well-established asso-
ciation between HCV infection and primary liver cancer. We 
also rendered support to the suggested association between 
HCV infection and NHL. Finally, we found HCV infection 
to be associated with a range of smoking- and alcohol-related 
cancers (cancers of the pancreas, lungs, kidneys, and oropha-
ryngeal region) but not with any other cancers.
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Appendix 1 ICD-7 codes for subgroups of cancers
Hematological cancers Immune-related cancers
Non-Hodgkin lymphoma (200, 202) Cervix uteri (171)
Leukemia (204) Melanoma of skin (190)
Other skin (191)
Liver-cancer
Liver, primary (155.0) Other cancers∗
Liver, not specified as primary (156) Gallbladder (155.1)
Peritoneum and unspecified (158–159)
Alcohol- and tobacco-related cancers Mediastinum (164)
Oropharyngeal (140–148) Breast (170)
Esophagus (150) Corpus uteri (172)
Colon, including recto sigmoid (153) Ovary (175)
Rectum, excluding anus (154) Prostate (177)
Pancreas (157) Testis (178)
Lung (162.0–162.1) Other and unspecified male genitals (179)
Kidney (180) Brain and nervous system (193)
Bladder (181) Thyroid (194)
Metastases (198)
Other and unspecified site (199)
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